Myriad Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit myriad-oncology.com/myriad-oncology-live for a list of dates, times, and subjects.
Links referenced and shared in this episode:
Bratslavsky et al. Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer. 2021 Nov 1;127(21):3957-3966. doi: 10.1002/cncr.33679. Epub 2021 Aug 3. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33679
Carlo MI, Mukherjee S, Mandelker D, et al. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncol. 2018;4(9):1228-1235. doi:10.1001/jamaoncol.2018.1986 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584283/
Cryoablation versus Partial Nephrectomy for Clinical Stage T1 Renal Masses: A Systematic Review and Meta-Analysis, https://pubmed.ncbi.nlm.nih.gov/30854132/